Ranbaxy to market new Daiichi Sankyo antibiotic in Romania

Newsroom 22/07/2010 | 13:51

Pharmaceutical companies Daiichi Sankyo and Ranbaxy announced plans to leverage Ranbaxy’s presence in Romania to market antibiotic Tavanic (levofloxacin), a synthetic antibacterial agent used to treat a broad range of infections.

The decision came after which Daiichi Sankyo and Sanofi-Aventis have agreed early this year to transfer the marketing rights of Tavanic in Romania and South Africa from Sanofi-Aventis to Ranbaxy.

Daiichi Sankyo worked with Sanofi-Aventis since 1993 for the manufacture and sales of levofloxacin covering Europe, Africa, Middle East, South America and part of Asia.

The transfer is expected to be effective in August 2010 for Romania. Commercialization of Tavanic by Sanofi-Aventis remains unchanged in the other territories. 


Dana Ciuraru

BR Magazine | Latest Issue

Download PDF: Business Review Magazine December (II) 2023 Issue

The December (II) 2023 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “A Visionary Leader Entrusted With Consolidating CPI's Portfolio
Newsroom | 21/12/2023 | 14:13
Advertisement Advertisement
Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue